Second interim analysis in 751 adults with 1p/19q non-co-deleted anaplastic glioma: concurrent temozolomide with radiotherapy was futile (median OS 66·9 vs 60·4 months; HR 0·97), while adjuvant temozolomide improved OS (82·3 vs 46·9 months; HR 0·64).
RCTn = 751
van den Bent et al. Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 study